Athletics Athlete Suspended for the Presence of Clenbuterol and Tamoxifen

(Ottawa, Ontario – June 2, 2020) – The Canadian Centre for Ethics in Sport (CCES) announced today that Graeme Thompson, an athletics athlete, received a two-year sanction for an anti-doping rule violation. The athlete’s urine sample, collected during in-competition doping control on July 27, 2019, revealed the presence of clenbuterol, a prohibited anabolic agent, and tamoxifen, a prohibited hormone and metabolic modulator.

In accordance with Canadian Anti-Doping Program (CADP) Rule 10.2.1, the standard sanction for the presence of the above referenced substances is a four-year period of ineligibility. However, based on information provided by the athlete, the CCES determined that the violation was not intentional and therefore proposed a sanction of two years ineligibility from sport (in accordance with CADP Rule 10.2.2). In response to the CCES’s notification of the adverse analytical finding, Mr. Thompson waived his right to a hearing and accepted the proposed sanction, which terminates on October 9, 2021. During the sanction period, the athlete, who resides in Port Hope, ON, is ineligible to participate in any capacity with any sport signatory to the CADP, including training with teammates.

In compliance with rule 7.10 of the CADP, the CCES’s file outcome summary can be found in the Canadian Sport Sanction Registry.

About the CCES
The CCES is an independent, national, not-for profit organization with a responsibility to administer the CADP. Under the CADP rules, the CCES announces publicly every anti-doping rule violation. We recognize that true sport can make a great difference for individuals, communities and our country. We are committed to making sport better by working collaboratively to activate a values-based and principle-driven sport system; protecting the integrity of sport from the negative forces of doping and other unethical threats; and advocating for sport that is fair, safe and open to everyone.

-- 30 --


For further information, please contact:

Megan Cumming
Corporate Communications Manager
+1 613-521-3340 x3233
[email protected]